■曲安奈德(PSTA)后筋膜下注射通常用于治疗难治性黄斑水肿。并发症可能源于手术以及眼周类固醇药物的使用。副作用包括结膜下出血,白内障进展,巩膜穿孔(导致视网膜下,亚类,或玻璃体内注射药物),视网膜脱离,上睑下垂,眼眶脂肪脱垂,眼眶脓肿,传染性巩膜炎,高眼压,和巩膜脓肿.在这里,我们描述了从PSTA程序中无意的视网膜下曲安奈德(TA)沉积而没有任何不利的视力威胁结果的情况。
■我们报告了一位患者,他有左眼颞上黄斑脱离孔源性视网膜脱离的病史,用巩膜带扣(SB)成功修复,平坦部玻璃体切除术,和气体放置。由于持续性复视,SB在术后1年后被移除。由于黄斑囊样水肿的发展,在患者局部类固醇和NSAIDs失败后进行PSTA.由于注射期间的意外阻力,该程序提前停止。扩张的眼底检查显示存在视网膜下曲安奈德。观察到患者,发现3个月后曲安奈德几乎完全消退,没有并发症。
■在以前的SB患者中,重要的是要强调全球渗透的风险,视网膜下沉积的TA,视网膜破裂的形成,或通过后腱膜下注射重新打开先前的视网膜破裂,这可能会对局部视网膜产生不利影响以及视网膜脱离的风险。
UNASSIGNED: Posterior subtenon injection of triamcinolone acetonide (PSTA) is commonly done to treat refractory cases of macular edema. Complications may arise from the procedure as well as from the use of the periocular steroid medications. Side effects include subconjunctival hemorrhage, progression of cataract, scleral perforation (resulting in subretinal, subhyaloid, or intravitreal injection of the drug), retinal detachment, ptosis, orbital fat prolapse, orbital abscess, infectious scleritis, ocular hypertension, and scleral abscess. Here we describe a case of inadvertent subretinal triamcinolone acetonide (TA) deposition from a PSTA procedure without any adverse vision-threatening outcomes.
UNASSIGNED: We report a patient who presented with a history of superior temporal left eye macula-off rhegmatogenous retinal detachment, which was successfully repaired with a scleral buckle (SB), pars plana vitrectomy, and gas placement. Due to persistent diplopia, the SB was removed after 1 year post-operatively. Due to the development of cystoid macular edema, a PSTA was performed after the patient failed topical steroids and NSAIDs. The procedure was halted early due to unexpected resistance during the injection. A dilated fundus exam showed the presence of subretinal triamcinolone acetonide. The patient was observed and found to have no complications with almost complete resolution of the triamcinolone acetonide after 3 months.
UNASSIGNED: In previous SB patients, it is important to highlight the risk of globe penetration, subretinal deposition of TA, formation of retinal breaks, or reopening of prior retinal breaks with posterior subtenon injection, which could have adverse effects on the local retina as well as the risk of retinal detachment.